<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Necitumumab: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Necitumumab: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Necitumumab: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="105703" href="/d/html/105703.html" rel="external">see "Necitumumab: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F45695272"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Cardiopulmonary arrest:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Cardiopulmonary arrest and/or sudden death occurred in 3% of patients treated with necitumumab in combination with gemcitabine and cisplatin. Closely monitor serum electrolytes, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after necitumumab administration.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypomagnesemia:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Hypomagnesemia occurred in 83% of patients receiving necitumumab in combination with gemcitabine and cisplatin, and was severe in 20% of patients. Monitor patients for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of necitumumab during treatment and for at least 8 weeks following completion of necitumumab. Withhold necitumumab for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as medically appropriate.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F45820933"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Portrazza</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F45695280"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antineoplastic Agent, Epidermal Growth Factor Receptor (EGFR) Inhibitor;</li>
<li>
                        Antineoplastic Agent, Monoclonal Antibody</li></ul></div>
<div class="block doa drugH1Div" id="F45746067"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> For patients with a prior grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent). For patients with a recurrent grade 1 or 2 infusion reaction, premedicate (prior to all subsequent necitumumab infusions) with diphenhydramine (or equivalent), acetaminophen, and dexamethasone (or equivalent).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3ac928cc-a5fe-47d5-847f-e5abed320440">Non–small cell lung cancer, metastatic</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Non–small cell lung cancer (squamous), metastatic:</b>
<b>IV:</b> 800 mg on days 1 and 8 of each 3-week treatment cycle (in combination with gemcitabine and cisplatin); continue until disease progression or unacceptable toxicity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26045340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26045340'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">In the study, gemcitabine and cisplatin were administered for a maximum of 6 cycles, while patients without disease progression continued necitumumab as single-agent therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26045340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26045340'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50991894"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling; however, based on pharmacokinetics, dosage adjustment is not likely necessary. </p></div>
<div class="block doha drugH1Div" id="F50989038"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling; however, based on pharmacokinetics, dosage adjustment is not likely necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment: There is no dosage adjustment provided in the manufacturer’s labeling (has not been studied).</p></div>
<div class="block dot drugH1Div" id="F45746071"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dermatologic toxicity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 rash or acneiform rash: Withhold necitumumab treatment until symptoms resolve to grade 2 or lower, then resume necitumumab with the dose reduced to 400 mg for at least 1 treatment cycle. If symptoms do not worsen, may increase the dose to 600 mg and then 800 mg in subsequent cycles.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 rash or acneiform rash that does not resolve to grade 2 or lower within 6 weeks: Permanently discontinue necitumumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 rash or acneiform rash that worsens or is intolerable at the 400 mg dose: Permanently discontinue necitumumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 skin induration/fibrosis: Permanently discontinue necitumumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 4 dermatologic toxicity: Permanently discontinue necitumumab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Electrolyte abnormality:</b> Grade 3 or 4 electrolyte abnormality: Withhold necitumumab treatment; may resume when electrolyte abnormality has improved to grade 2 or lower (replete electrolytes as appropriate).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Infusion-related reactions:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Grade 1: Reduce necitumumab infusion rate by 50%.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 2: Interrupt necitumumab infusion until signs/symptoms have resolved to grade 1 or 0, then resume with the rate reduced by 50% for all subsequent infusions.</p>
<p style="text-indent:-2em;margin-left:4em;">Grade 3 or 4: Permanently discontinue necitumumab.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Thromboembolic events:</b> Serious or life-threatening venous thromboembolism or arterial thromboembolism: Discontinue treatment necitumumab.</p></div>
<div class="block doe drugH1Div" id="F45746068"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;display:inline">Refer to adult dosing.</p></div>
<div class="block adr drugH1Div" id="F45760200"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reaction percentages reported as part of a combination regimen with gemcitabine and cisplatin.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Headache (11%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin toxicity (79%; grades 3/4: 8%), skin rash (44%; grades 3/4: 4%), acneiform eruption (15%; grades 3/4: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Hypomagnesemia (43% to 83%; grades 3/4: 20%), hypocalcemia (45%; grades 3/4: 6%; with albumin corrected: 36%; grades 3/4: 4%), hypophosphatemia (31%; grades 3/4: 8%), hypokalemia (28%; grades 3/4: 5%), weight loss (13%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Vomiting (29%), diarrhea (16%), stomatitis (11%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Venous thromboembolism (9%; grades 3/4: 5%), arterial thromboembolism (5%; grades 3/4: 4%), pulmonary embolism (5%), cardiorespiratory arrest (3%), deep vein thrombosis (2%), cerebrovascular accident (≤2%), ischemia (≤2%), myocardial infarction (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris (9%), paronychia (7%), pruritus (7%), xeroderma (7%), skin fissure (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Immunologic: Antibody development (4%; neutralizing: 1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Conjunctivitis (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hemoptysis (10%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Infusion related reaction (2%; grade 3: &lt;1%)</p></div>
<div class="block coi drugH1Div" id="F45695274"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">There are no contraindications listed in the manufacturer's labeling.</p></div>
<div class="block war drugH1Div" id="F45741447"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Cardiopulmonary arrest: [US Boxed Warning]: Cardiopulmonary arrest and/or sudden death occurred in a small percentage of patients treated with necitumumab in combination with gemcitabine and cisplatin. Monitor serum electrolytes closely, including serum magnesium, potassium, and calcium, with aggressive replacement when warranted during and after necitumumab administration.</b> Continue electrolyte monitoring for at least 8 weeks after the last dose. Some cardiopulmonary events were fatal; many of those patients had comorbid conditions (including a history of coronary artery disease, hypomagnesemia, chronic obstructive pulmonary disease, and/or hypertension). Patients with significant coronary artery disease, MI within 6 months, uncontrolled hypertension or uncontrolled heart failure were excluded from the squamous cell non-small cell lung cancer (NSCLC) study.</p>
<p style="text-indent:-2em;margin-left:4em;">• Dermatologic toxicity: Dermatologic toxicity, including rash, dermatitis acneiform, acne, dry skin, pruritus, generalized rash, skin fissures, maculo-papular rash, and/or erythema occurs commonly; may be severe. Skin toxicity usually developed within the first 2 weeks of treatment and resolved within 17 weeks after onset. May require treatment interruption, dose reduction, or discontinuation. Patients should minimize exposure to the sun.</p>
<p style="text-indent:-2em;margin-left:4em;">• <b>Hypomagnesemia: [US Boxed Warning]: Hypomagnesemia occurred in a majority of patients receiving necitumumab in combination with gemcitabine and cisplatin; hypomagnesemia was severe in one-fifth of patients. Monitor for hypomagnesemia, hypocalcemia, and hypokalemia prior to each dose of necitumumab during treatment and for at least 8 weeks following completion of necitumumab. Withhold necitumumab for Grade 3 or 4 electrolyte abnormalities. Replete electrolytes as appropriate.</b> May resume treatment when hypomagnesemia and related electrolyte abnormalities are improved to grade 2 or lower. The median time to development of hypomagnesemia was 6 weeks after treatment initiation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Infusion reactions: Infusion-related reactions have been reported with necitumumab, usually after the first or second infusion. Premedication was not routinely administered prior to the first dose in the squamous cell NSCLC study. Monitor for signs/symptoms of infusion reaction. Discontinue for serious or life-threatening reactions.</p>
<p style="text-indent:-2em;margin-left:4em;">• Thromboembolism: Venous and arterial thromboembolic events (VTE and ATE) were observed with necitumumab, including grades 3 and 4 events and some fatalities. The most common VTEs were deep vein thrombosis and pulmonary embolism and the most common ATEs were cerebral stroke and ischemia and MI. Discontinue necitumumab for serious or life-threatening VTE or ATE. The incidence of VTE may be higher in patients ≥70 years of age (compared to patients under age 70).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Non-squamous NSCLC: Necitumumab is not indicated for use in patients with non-squamous NSCLC. In a study of necitumumab in combination with pemetrexed and cisplatin for the treatment of metastatic non-squamous NSCLC, patients experienced increased serious and fatal toxicities and cardiopulmonary arrest/sudden death within 30 days of the last dose of necitumumab (compared to pemetrexed and cisplatin without necitumumab).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p></div>
<div class="block dosfc drugH1Div" id="F46781100"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">Portrazza is produced in genetically engineered mammalian NS0 cells.</p></div>
<div class="block foc drugH1Div" id="F45820934"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Intravenous [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Portrazza: 800 mg/50 mL (50 mL) [contains polysorbate 80]</p></div>
<div class="block geq drugH1Div" id="F45820932"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F46105222"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Solution</b> (Portrazza Intravenous)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">800 mg/50 mL (per mL): $103.91</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block adm drugH1Div" id="F45746073"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">IV: Infuse over 60 minutes using an infusion pump. Infuse through a separate line. Flush with sodium chloride 0.9% at the end of infusion. Do not infuse with other medications or with electrolytes. Monitor for infusion reactions; reduce infusion rate by 50% for grade 1 infusion reaction; interrupt infusion for grade 2 infusion reaction.</p>
<p style="text-indent:-2em;margin-left:2em;">Necitumumab should be administered prior to gemcitabine and cisplatin (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26045340']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26045340'])">Ref</a></span>).</p></div>
<div class="block use drugH1Div" id="F45695268"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Non-small cell lung cancer (squamous), metastatic:</b> First-line treatment of metastatic squamous non-small cell lung cancer (NSCLC) in combination with gemcitabine and cisplatin</p>
<p style="text-indent:-2em;margin-left:2em;">Limitations of use: Not indicated for treatment of non-squamous NSCLC.</p></div>
<div class="block mst drugH1Div" id="F45741443"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Necitumumab may be confused with bevacizumab, nivolumab, pembrolizumab, ramucirumab.</p>
<p style="text-indent:-2em;margin-left:4em;">Portrazza may be confused with Arzerra.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F45733088"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F45733085"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Efgartigimod Alfa: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rozanolixizumab: May diminish the therapeutic effect of Fc Receptor-Binding Agents.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308489"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Females of reproductive potential should use effective contraception during therapy and for 3 months after the last necitumumab dose.</p></div>
<div class="block pri drugH1Div" id="F45741445"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Necitumumab is expected to cross the placenta. Based on the mechanism of action and data from animal reproduction studies, in utero exposure to necitumumab may cause fetal harm.</p></div>
<div class="block brc drugH1Div" id="F45741446"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if necitumumab is present in breast milk; however, human IgG antibodies can be detected in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer during therapy or for 3 months after the last necitumumab dose.</p></div>
<div class="block mop drugH1Div" id="F45746076"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Serum electrolytes, including magnesium, potassium, and calcium (prior to each dose during treatment and for at least 8 weeks following completion). Monitor for signs/symptoms of infusion-related reactions, dermatologic toxicity, and thromboembolism.</p>
<p style="text-indent:-2em;margin-left:2em;">The American Society of Clinical Oncology hepatitis B virus (HBV) screening and management provisional clinical opinion (ASCO [Hwang 2020]) recommends HBV screening with hepatitis B surface antigen, hepatitis B core antibody, total Ig or IgG, and antibody to hepatitis B surface antigen prior to beginning (or at the beginning of) systemic anticancer therapy; do not delay treatment for screening/results. Detection of chronic or past HBV infection requires a risk assessment to determine antiviral prophylaxis requirements, monitoring, and follow-up.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular monitoring: Comprehensive assessment prior to treatment including a history and physical examination, screening for cardiovascular disease risk factors such as hypertension, diabetes, dyslipidemia, obesity, and smoking (ASCO [Armenian 2017]; ESC [Lyon 2022]).</p></div>
<div class="block pha drugH1Div" id="F45744652"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Necitumumab is a recombinant human IgG1 EGFR monoclonal antibody which binds (with a high affinity) to the ligand binding site of the EGFR receptor to prevent receptor activation and downstream signaling (Thatcher 2015).</p></div>
<div class="block phk drugH1Div" id="F45744654"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>dss</sub>: 7 L.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: ~14 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Clearance (mean): 14.1 mL/hour.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F49940063"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Portrazza</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27918725">
<a name="27918725"></a>Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/27918725/pubmed" id="27918725" target="_blank">27918725</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32716741">
<a name="32716741"></a>Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. <i>J Clin Oncol</i>. 2020;38(31):3698-3715. doi:10.1200/JCO.20.01757<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/32716741/pubmed" id="32716741" target="_blank">32716741</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313. doi: 10.1034/j.1600-0536.2002.4705104.x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36017568">
<a name="36017568"></a>Lyon AR, López-Fernández T, Couch LS, et al; ESC Scientific Document Group. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). <i>Eur Heart J.</i> 2022;43(41):4229-4361. doi:10.1093/eurheartj/ehac244<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/36017568/pubmed" id="36017568" target="_blank">36017568</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Portrazza (necitumumab) [prescribing information]. Indianapolis, IN: Eli Lilly and Company; November 2015.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8960):1312-1313. doi: 10.1016/s0140-6736(95)90963-x.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26045340">
<a name="26045340"></a>Thatcher N, Hirsch FR, Luft AV, et al; SQUIRE Investigators. Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial. <i>Lancet Oncol</i>. 2015;16(7):763-774. doi: 10.1016/S1470-2045(15)00021-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/necitumumab-drug-information/abstract-text/26045340/pubmed" id="26045340" target="_blank">26045340</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 105609 Version 77.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
